Healthcare Coalition Calls for Clearer Guidelines on Biosimilar Interchangeability to Address Public Confusion

A coalition of healthcare industry groups has expressed concerns regarding the current legislation on the interchangeability of biosimilars with their name-brand biologic counterparts. They argue that this regulatory framework has led to significant public confusion about the safety of biosimilars. This issue was highlighted in a letter the groups sent to lawmakers on Monday. The letter emphasizes the necessity for clearer guidelines and improved communication to inform the public about the safety and efficacy of biosimilars, which can play a crucial role in reducing healthcare costs and increasing access to treatment options. For more detailed information, you can read the full article on Law360.